

| Package | Price per Dose | Price | |
|---|---|---|---|
| 360 pills | £0.52 | £267.52 £187.26 Free shipping | |
| 270 pills | £0.55 | £213.69 £149.58 Free shipping | |
| 180 pills | £0.63 | £163.04 £114.13 | |
| 120 pills | £0.71 | £121.88 £85.31 | |
| 90 pills | £0.75 | £96.55 £67.58 | |
| 60 pills | £0.83 | £71.22 £49.85 | |
| 30 pills | £0.93 | £39.56 £27.69 | |
| 360 pills | £0.55 | £284.93 £199.45 Free shipping | |
| 270 pills | £0.59 | £226.36 £158.45 Free shipping | |
| 180 pills | £0.64 | £164.62 £115.23 | |
| 120 pills | £0.72 | £123.46 £86.42 | |
| 90 pills | £0.80 | £102.88 £72.02 | |
| 60 pills | £0.86 | £74.39 £52.07 | |
| 30 pills | £0.99 | £42.73 £29.91 | |
| 360 pills | £0.72 | £370.41 £259.29 Free shipping | |
| 270 pills | £0.75 | £291.26 £203.88 Free shipping | |
| 180 pills | £0.82 | £210.53 £147.37 | |
| 120 pills | £0.91 | £155.12 £108.58 | |
| 90 pills | £0.96 | £123.46 £86.42 | |
| 60 pills | £1.07 | £91.80 £64.26 | |
| 30 pills | £1.17 | £50.64 £35.45 |
Enalapril is a prodrug that is converted in the liver to the active angiotensin-converting enzyme inhibitor enalaprilat, a property that underpins its pharmacology. It was among the first ACE inhibitors introduced for cardiovascular disease management in the 1980s and remains one of the most widely prescribed therapies for hypertension and heart failure, reflecting its robust antihypertensive and cardioprotective profile.
Enalapril is an orally active ACE inhibitor. As a prodrug, it is rapidly hydrolyzed to enalaprilat, the pharmacologically active moiety, after absorption from the gastrointestinal tract. By inhibiting ACE, enalaprilat reduces the production of angiotensin II and suppresses aldosterone secretion, producing vasodilation, decreased systemic vascular resistance, and favorable remodeling of cardiac and vascular tissue.
Therapeutically, enalapril is used to lower elevated blood pressure and to improve symptoms and outcomes in certain heart conditions. Its pharmacodynamic effect includes reduced afterload, better renal perfusion in selected settings, and modulation of neurohormonal pathways that contribute to heart failure progression. The active metabolite is predominantly cleared by the kidneys, and dosing typically requires adjustment in individuals with impaired renal function. In hepatic impairment, careful selection and monitoring are advised because activation depends on hepatic hydrolysis of the prodrug.
Enalapril is indicated for the treatment of essential hypertension to lower blood pressure and reduce cardiovascular risk. It is also used in symptomatic heart failure to improve functional status and exercise tolerance, as part of a comprehensive heart-failure management plan. In patients with a history of myocardial infarction and left ventricular dysfunction, enalapril can improve survival and reduce the likelihood of adverse remodeling. Additionally, ACE inhibitors including enalapril are employed to slow the progression of diabetic nephropathy in hypertensive patients by lowering intraglomerular pressure and proteinuria.
Clinical practice supports using enalapril as part of combination therapy when indicated, with careful consideration of comorbidities such as renal impairment, diabetes, and electrolyte disorders. The medication is contraindicated in pregnancy due to fetal risk and requires careful monitoring in the elderly and in those with dehydration or concomitant diuretic therapy. Overall, the choice to use enalapril rests on balancing blood-pressure control with preservation of renal function and avoidance of adverse neurohormonal effects.
Initiation and titration should be individualized to the patient’s blood pressure response and tolerance. For uncomplicated hypertension, a common starting approach is a small daily dose, followed by gradual uptitration over 1–2 weeks to achieve target blood pressure. In heart failure or LV dysfunction, starting doses are lower, with slow up-titration as tolerated, to minimize symptomatic hypotension and kidneys’ responses. Typical daily dosing ranges extend up to 40 mg per day for hypertension, and higher doses may be used in some heart-failure regimens under supervision.
Administration is oral, and treatment may be taken with or without food. Consistency in timing helps maintain stable plasma levels and blood-pressure control, so patients are advised to take enalapril at the same time each day if possible. If a dose is missed, take it as soon as remembered unless the next dose is due soon; do not double the dose to catch up. Avoid abrupt cessation without medical guidance, as abrupt withdrawal can lead to rebound hypertension or heart-failure symptoms.
Storage should be at room temperature, in a dry place, away from light, and out of reach of children. Keep the medication in its original container with the pharmacist’s label intact. Before initiating therapy, and periodically thereafter, clinicians typically assess renal function and electrolytes; dose adjustments may be required in cases of renal impairment. Pregnancy must be avoided during enalapril therapy; if pregnancy is planned or suspected, discontinue and consult a clinician promptly. Clinicians may advise avoiding NSAIDs and ensuring adequate hydration, especially during heat or illness, to protect kidney function while on therapy.
Common adverse effects include dizziness or lightheadedness, particularly after standing up (orthostatic effects), fatigue, and a persistent dry cough. Some patients notice changes in kidney function or higher potassium levels, which can cause muscle weakness or irregular heart rhythms if not monitored. Less frequent symptoms include nausea, skin rash, or facial flushing. Overall, many people tolerate enalapril well, but monitoring helps identify issues early and prevent complications.
Serious, though uncommon, adverse events require immediate medical attention. Angioedema—swelling of the lips, tongue, throat, or trouble breathing—can occur, more often in certain racial groups, and warrants urgent evaluation. Hyperkalemia, symptomatic hypotension, and acute kidney injury may occur, especially when used with other kidney-harming drugs or with dehydration. In pregnancy, ACE inhibitors can cause fetal injury or death and must be avoided.
Seek medical advice promptly if you experience symptoms suggestive of angioedema (swelling of the face or throat, difficulty breathing), persistent or worsening dizziness or fainting, severe or persistent cough, swelling, weight gain, reduced urination, or signs of kidney injury (dark urine, swelling in ankles/feet). Contact emergency services for rapid onset breathing difficulties or severe swelling.
Regular follow-up with a clinician is important during enalapril therapy. Routine monitoring typically includes blood pressure checks, assessment of kidney function (creatinine), and electrolyte levels (especially potassium). Do not use enalapril during pregnancy; if pregnancy occurs or is planned, discuss alternative therapies with a healthcare professional. If you are taking diuretics or other cardiac or renal medications, inform your clinician, as dose adjustments or monitoring may be required to minimize adverse interactions.
14–21 days. Free from £147.75 .
5–9 days. £22.16
−10% when paying with cryptocurrency.
−10% on all repeat orders.
All orders are packed in neutral, unbranded boxes with no product name on the outside.
